{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:10:37Z","timestamp":1791360637075,"version":"4.3.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,9,25]],"date-time":"2027-09-25T00:00:00Z","timestamp":1821830400000},"content-version":"am","delay-in-days":359,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100017540","name":"National Heart Lung and Blood Institute Division of Intramural Research","doi-asserted-by":"publisher","award":["T32HL007227"],"award-info":[{"award-number":["T32HL007227"]}],"id":[{"id":"10.13039\/100017540","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","heartrhythmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Rhythm"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.hrthm.2026.04.033","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T16:20:15Z","timestamp":1776961215000},"page":"e2613-e2621","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["New and recurrent atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy receiving mavacamten"],"prefix":"10.1016","volume":"23","author":[{"given":"Syed","family":"Bukhari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Gasperetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryana","family":"Rivers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine C.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas S.","family":"Barth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Madrazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5589-1216","authenticated-orcid":false,"given":"Richard T.","family":"Carrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hrthm.2026.04.033_bib1","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1161\/CIRCULATIONAHA.117.029267","article-title":"Clinical profile and consequences of atrial fibrillation in hypertrophic cardiomyopathy","volume":"136","author":"Rowin","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2026.04.033_bib2","doi-asserted-by":"crossref","first-page":"e1239","DOI":"10.1161\/CIR.0000000000001250","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology joint committee on clinical practice guidelines","volume":"149","author":"Ommen","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2026.04.033_bib3","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.amjcard.2022.05.032","article-title":"Ventricular septal myectomy decreases long-term risk for atrial fibrillation in patients with hypertrophic cardiomyopathy","volume":"179","author":"Rowin","year":"2022","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hrthm.2026.04.033_bib4","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1016\/j.athoracsur.2021.08.081","article-title":"Patient-reported atrial fibrillation after septal myectomy for hypertrophic cardiomyopathy","volume":"113","author":"Sun","year":"2022","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.hrthm.2026.04.033_bib5","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","article-title":"Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy","volume":"80","author":"Desai","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2026.04.033_bib6","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.hrthm.2026.04.033_bib7","doi-asserted-by":"crossref","first-page":"H881","DOI":"10.1152\/ajpheart.00345.2020","article-title":"Mavacamten decreases maximal force and Ca2+ sensitivity in the N47K-myosine regulatory light chain mouse model of hypertrophic cardiomyopathy","volume":"320","author":"Awinda","year":"2021","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.hrthm.2026.04.033_bib8","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jacep.2024.10.014","article-title":"Atrial fibrillation in patients receiving mavacamten for obstructive hypertrophic cardiomyopathy: real-world incidence, management, and outcomes","volume":"11","author":"Boyle","year":"2025","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.hrthm.2026.04.033_bib9","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.hrthm.2024.04.055","article-title":"Incidence of newly recognized atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy treated with Mavacamten","volume":"21","author":"Castrichini","year":"2024","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrthm.2026.04.033_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.cardfail.2026.02.035","article-title":"Incidence and outcomes of atrial fibrillation and systolic dysfunction in patients receiving mavacamten for obstructive hypertrophic cardiomyopathy: A multicenter study","author":"Nguyen","year":"2026","journal-title":"J Card Fail"},{"key":"10.1016\/j.hrthm.2026.04.033_bib11","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.125.042488","article-title":"Characteristics and outcomes of mavacamten use in 2440 patients with obstructive hypertrophic cardiomyopathy","volume":"14","author":"Mahana","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.hrthm.2026.04.033_bib12","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.125.044537","article-title":"Real-world observations in patients with obstructive hypertrophic cardiomyopathy treated with mavacamten: evidence of favorable disease modification","volume":"14","author":"Desai","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.hrthm.2026.04.033_bib13","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.120.009796","article-title":"Development and validation of a clinical predictive model for identifying hypertrophic cardiomyopathy patients at risk for atrial fibrillation: the HCM-AF score","volume":"14","author":"Carrick","year":"2021","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.hrthm.2026.04.033_bib14","doi-asserted-by":"crossref","first-page":"e841","DOI":"10.1016\/j.hrthm.2025.05.046","article-title":"External validation of atrial fibrillation risk prediction tools in a racially diverse cohort of patients with hypertrophic cardiomyopathy","volume":"22","author":"Pronovost","year":"2025","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrthm.2026.04.033_bib15","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.034069","article-title":"Eighteen-month real-world experience using mavacamten for treatment of obstructive hypertrophic cardiomyopathy in a racially diverse population","volume":"13","author":"Ramonfaur","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.hrthm.2026.04.033_bib16","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1093\/eurheartj\/ehae579","article-title":"Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy","volume":"45","author":"Garcia-Pavia","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hrthm.2026.04.033_bib17","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1161\/CIRCULATIONAHA.124.072445","article-title":"Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: Week 128 results from VALOR-HCM","volume":"151","author":"Desai","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2026.04.033_bib18","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/jce.15304","article-title":"Impact of comorbidities on atrial fibrillation and sudden cardiac death in hypertrophic cardiomyopathy","volume":"33","author":"Sridharan","year":"2022","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.hrthm.2026.04.033_bib19","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1136\/heartjnl-2016-309672","article-title":"Predictors of atrial fibrillation in hypertrophic cardiomyopathy","volume":"103","author":"Guttmann","year":"2017","journal-title":"Heart"},{"key":"10.1016\/j.hrthm.2026.04.033_bib20","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001002","article-title":"Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical correlations, and mortality in a large high-risk population","volume":"3","author":"Siontis","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.hrthm.2026.04.033_bib21","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jcmg.2024.08.005","article-title":"Mavacamten-associated temporal changes in left atrial function in obstructive HCM: insights from the VALOR-HCM trial","volume":"18","author":"Desai","year":"2025","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.hrthm.2026.04.033_bib22","first-page":"e506","article-title":"2015 ACC\/AHA\/HRS guideline for the management of adult patients with supraventricular tachycardia: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society","volume":"133","author":"Page","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2026.04.033_bib23","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.hrthm.2025.08.031","article-title":"Low incidence of atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy treated with aficamten: an analysis from the REDWOOD-HCM, SEQUOIA-HCM, and FOREST-HCM trials","volume":"23","author":"Rowin","year":"2026","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrthm.2026.04.033_bib24","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jacc.2022.10.020","article-title":"Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy","volume":"81","author":"Maron","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2026.04.033_bib25","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","article-title":"Aficamten for symptomatic obstructive hypertrophic cardiomyopathy","volume":"390","author":"Maron","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrthm.2026.04.033_bib26","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.3390\/biomedicines13071619","article-title":"Comprehensive review: mavacamten and aficamten in hypertrophic cardiomyopathy","volume":"13","author":"Savsin","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.hrthm.2026.04.033_bib27","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1093\/eurheartj\/ehad637","article-title":"Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy","volume":"44","author":"Braunwald","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hrthm.2026.04.033_bib28","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/s44161-024-00505-0","article-title":"Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy","volume":"3","author":"Hartman","year":"2024","journal-title":"Nat Cardiovasc Res"}],"container-title":["Heart Rhythm"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1547527126022836?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1547527126022836?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T08:42:53Z","timestamp":1790325773000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1547527126022836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1547527126022836"],"URL":"https:\/\/doi.org\/10.1016\/j.hrthm.2026.04.033","relation":{},"ISSN":["1547-5271"],"issn-type":[{"value":"1547-5271","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New and recurrent atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy receiving mavacamten","name":"articletitle","label":"Article Title"},{"value":"Heart Rhythm","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hrthm.2026.04.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Heart Rhythm Society. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}